{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T12:16:12Z","timestamp":1680869772660},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Introduction<\/jats:bold>. Renal osteodystrophy is a severe complication of chronic kidney disease (CKD) that increases morbidity and mortality in these patients. Mineral and bone disorder starts early in CKD and affects the incidence of bone fractures. The aim of this study was to observe the frequency of diverse bone fractures in patients with CKD not on dialysis.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods<\/jats:bold>. This cohort study included 68 patients that were followed during the two-year period. The patients were divided into two cohorts: one that developed bone fractures and the other that did not. There were 35 (51.5%) men and 33 (48.5%) women. The mean age of patients ranged 62.88\u00b111.60 years. During follow-up serum values of chronic kidney disease \u2013 mineral and bone indicators were measured. The methods of descriptive and analytical statistics were used in order to analyze obtained data.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results<\/jats:bold>. During this two-year follow-up seven patients developed bone fractures. Among them, females dominated (6 patients) compared to males (only 1 patient). The most common were fractures of forearm. The mean level of parathyroid hormone (PTH) at the beginning of the monitoring was higher in the group of patients with bone fractures (165.25 \u00b1 47.69 pg\/mL) in regard to another group (103.96 \u00b1 81.55 pg\/mL). After two-year follow-up, this difference became statistically significant at the level p &lt; 0.05. Patients that developed bone fractures had higher FRAX (Fracture Risk Assessment) score compared to another group.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusion<\/jats:bold>. In our study, about 10% of patients had bone fractures in the two-year follow-up period. Patients who developed fractures had a higher PTH level and FRAX score.<\/jats:p>","DOI":"10.1515\/rjim-2017-0021","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T13:20:42Z","timestamp":1496409642000},"page":"222-228","source":"Crossref","is-referenced-by-count":4,"title":["The frequency of bone fractures among patients with chronic kidney disease not on dialysis: two-year follow-up"],"prefix":"10.1515","volume":"55","author":[{"given":"Andreja","family":"Figurek","sequence":"first","affiliation":[{"name":"Clinic for Internal Diseases, Department for Nephrology , University Clinical Centre of the Republic of Srpska , Banja Luka , Republic of Srpska, Bosnia and Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlastimir","family":"Vlatkovic","sequence":"additional","affiliation":[{"name":"Clinic for Internal Diseases, Department for Nephrology , University Clinical Centre of the Republic of Srpska , Banja Luka , Republic of Srpska, Bosnia and Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Vojvodic","sequence":"additional","affiliation":[{"name":"Clinic for Internal Diseases, Department for Nephrology , University Clinical Centre of the Republic of Srpska , Banja Luka , Republic of Srpska, Bosnia and Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Gasic","sequence":"additional","affiliation":[{"name":"Clinic for Internal Diseases, Department for Nephrology , University Clinical Centre of the Republic of Srpska , Banja Luka , Republic of Srpska, Bosnia and Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milorad","family":"Grujicic","sequence":"additional","affiliation":[{"name":"Clinic for Internal Diseases, Department for Nephrology , University Clinical Centre of the Republic of Srpska , Banja Luka , Republic of Srpska, Bosnia and Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"2021040609501621297_j_rjim-2017-0021_ref_001_w2aab3b7b2b1b6b1ab1ab1Aa","unstructured":"1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 (113):S1-130."},{"key":"2021040609501621297_j_rjim-2017-0021_ref_002_w2aab3b7b2b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. EKNOYAN G., LAMEIRE N., BARSOUM R., ECKARDT KU., LEVIN A., LEVIN N., et al. The burden of kidney disease: improving global outcomes. Kidney Int.2004; 66 (4):1310-4.10.1111\/j.1523-1755.2004.00894.x","DOI":"10.1111\/j.1523-1755.2004.00894.x"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_003_w2aab3b7b2b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. ANPALAHAN M., VENKATESAN S., ANPALAHAN A. Fragility fractures in chronic kidney disease: assesment and pharmacologic management. Advances in Nephrology. vol. 2014, Article ID 727135, 7 pages, 2014. doi:10.1155\/2014\/727135.","DOI":"10.1155\/2014\/727135"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_004_w2aab3b7b2b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. HAMDY NA., KANIS JA., BENETON MN., BROWN CB., JUTTMANN JR., JORDANS JG., et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995; 310:358-63.","DOI":"10.1136\/bmj.310.6976.358"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_005_w2aab3b7b2b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. OZMEN B. Use of bisphosphonates in chronic kidney disease. World J Nephrol Urol. 2012; 1 (1):1-7.","DOI":"10.4021\/wjnu5e"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_006_w2aab3b7b2b1b6b1ab1ab6Aa","unstructured":"6. Fracture Risk Assessment Tool. Centre for Metabolic Bone Diseases, University of Sheffield, UK. Available from: https:\/\/www.sheffield.ac.uk\/FRAX\/tool.aspx?country=9."},{"key":"2021040609501621297_j_rjim-2017-0021_ref_007_w2aab3b7b2b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. NICKOLAS TL., LEONARD MB., SHANE E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74 (6):721-31.10.1038\/ki.2008.264","DOI":"10.1038\/ki.2008.264"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_008_w2aab3b7b2b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. ALEM AM, SHERRARD DJ, GILLEN DL, WEISS NS, BERESFORD SA, HECKBERT SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396-9.10.1046\/j.1523-1755.2000.00178.x","DOI":"10.1046\/j.1523-1755.2000.00178.x"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_009_w2aab3b7b2b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. COCO M., RUSH H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115\u201321.","DOI":"10.1053\/ajkd.2000.19812"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_010_w2aab3b7b2b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. NICKOLAS TL., MCMAHON DJ., SHANE E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006; 17:3223-32.","DOI":"10.1681\/ASN.2005111194"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_011_w2aab3b7b2b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. ROBBINS J., ARAGAKI AK., KOOPERBERG C., WATTS N., WACTAWSKI-WENDE J., JACKSON RD., et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA2007; 298: 2389-98.","DOI":"10.1001\/jama.298.20.2389"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_012_w2aab3b7b2b1b6b1ab1ac12Aa","unstructured":"12. DEYL V., FARRAH TE., TRAYNOR JP., SPALDING EM., ROBERTSON SE., GEDDES CC. Symptomatic fracture risk in the renal replacement therapy population. Nephrol. Dial. Transplant. (2016). doi: 10.1093\/ndt\/gfw222.10.1093\/ndt\/gfw222"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_013_w2aab3b7b2b1b6b1ab1ac13Aa","unstructured":"13. AYUS JC., FUENTES NA., NEGRE AL., MORITY ML., GIUNTA DH., KALANTAR-ZADEH K., et al. Mild prolonged chronic hyponatremia and risk of hip fracture in the elderly. Nephrol. Dial. Transplant. (2016). doi: 10.1093\/ndt\/gfw029.10.1093\/ndt\/gfw029"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_014_w2aab3b7b2b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. RIX M., ANDREASSEN H., ESKILDSEN P., LANGDAHL B., OLGAARD K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999; 56:1084-1093.","DOI":"10.1046\/j.1523-1755.1999.00617.x"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_015_w2aab3b7b2b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. RUSSO CR., TACCETTI G., CANEVA P., MANNARINO A., MARANGHI P., RICCA M. Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Osteoporos Int. 1998; 8:443-8.","DOI":"10.1007\/s001980050089"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_016_w2aab3b7b2b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. JAMAL SA., GILBERT J., GORDON C., BAUER DC. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006; 21:543-8.","DOI":"10.1359\/jbmr.060105"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_017_w2aab3b7b2b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. MAGNUSSON P., SHARP CA., MAGNUSSON M., RISTELI J., DAVIE MW., LARSSON L. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001; 60:257-65.10.1046\/j.1523-1755.2001.00794.x","DOI":"10.1046\/j.1523-1755.2001.00794.x"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_018_w2aab3b7b2b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. MARUYAMA Y., TANIGUCHI M., KAZAMA JJ., YOKOYAMA K., HOSOYA T., YOKOO T., et al. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant. 2014; 29:1532-8.","DOI":"10.1093\/ndt\/gfu055"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_019_w2aab3b7b2b1b6b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. SARDIWAL S., MAGNUSSON P., GOLDSMITH DJ., LAMB EJ. Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis 2013; 62:810-22.10.1053\/j.ajkd.2013.02.366","DOI":"10.1053\/j.ajkd.2013.02.366"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_020_w2aab3b7b2b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. PARK JC., KOVESDY CP., DUONG U., STREJA E., RAMBOD M., NISSENSON AR., et al. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int 2010; 14:182-92.10.1111\/j.1542-4758.2009.00430.x","DOI":"10.1111\/j.1542-4758.2009.00430.x"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_021_w2aab3b7b2b1b6b1ab1ac21Aa","doi-asserted-by":"crossref","unstructured":"21. LERTDUMRONGLUK P., LAU WL., PARK J., RHEE CM., KOVESDY CP., KALANTAR-ZADEH K. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant 2013; 28:2535-45.","DOI":"10.1093\/ndt\/gft290"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_022_w2aab3b7b2b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. KOVESDY CP., URECHE V., LU JL., KALANTAR-ZADEH K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 25:3003-11.","DOI":"10.1093\/ndt\/gfq144"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_023_w2aab3b7b2b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. JADOUL M., ALBERT JM., AKIBA T., AKIZAWA T., ARAB L., BRAGG-GRESHAM JL., et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70:1358-66.","DOI":"10.1038\/sj.ki.5001754"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_024_w2aab3b7b2b1b6b1ab1ac24Aa","doi-asserted-by":"crossref","unstructured":"24. QI Q., MONIER-FAUGERE MC., GENG Z., MALLUCHE HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995; 26(4):622-31.10.1016\/0272-6386(95)90599-5","DOI":"10.1016\/0272-6386(95)90599-5"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_025_w2aab3b7b2b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. TORRES A., LORENZO V., HERNANDEZ D., RODRIGUEZ JC., CONCEPCION MT., RODRIGUEZ AP., et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney International.1995; 47 (5):1434-42.","DOI":"10.1038\/ki.1995.201"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_026_w2aab3b7b2b1b6b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. IIMORI S., MORI Y., AKITA W., KUYAMA T., TAKADA S., ASAI T., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients \u2013 a single-center cohort study. Nephrol Dial Transplant 2012; 27:345-51.","DOI":"10.1093\/ndt\/gfr317"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_027_w2aab3b7b2b1b6b1ab1ac27Aa","doi-asserted-by":"crossref","unstructured":"27. LIN JH. Bisphosponates: a review of their pharmacokinetic properties. Bone. 1996; 18(2):75-85.10.1016\/8756-3282(95)00445-9","DOI":"10.1016\/8756-3282(95)00445-9"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_028_w2aab3b7b2b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. CONTR P., GUARNERI V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. The Oncologist.2004; 9 (Suppl 4): 28-37.10.1634\/theoncologist.9-90004-28","DOI":"10.1634\/theoncologist.9-90004-28"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_029_w2aab3b7b2b1b6b1ab1ac29Aa","doi-asserted-by":"crossref","unstructured":"29. SHERRARD DJ., HERCZ G., PEI Y., MALONEY NA., GREENWOOD C., MANUEL A., et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int. 1993; 43(2):436-42.10.1038\/ki.1993.64","DOI":"10.1038\/ki.1993.64"},{"key":"2021040609501621297_j_rjim-2017-0021_ref_030_w2aab3b7b2b1b6b1ab1ac30Aa","doi-asserted-by":"crossref","unstructured":"30. LEVIN A., BAKRIS GL., MOLITCH M., SMULDERS M., TIAN J., WILIAMS LA., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71:31-8.","DOI":"10.1038\/sj.ki.5002009"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/rjim\/55\/4\/article-p222.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/rjim-2017-0021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T09:55:33Z","timestamp":1617702933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/rjim-2017-0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,11,15]]},"published-print":{"date-parts":[[2017,12,1]]}},"alternative-id":["10.1515\/rjim-2017-0021"],"URL":"https:\/\/doi.org\/10.1515\/rjim-2017-0021","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}